RESULT
Among the approved drug therapies for osteoporosis two classes of drugs
are mostly used that are anti resorptive agents (e.g., bisphosphonates,
estrogen, calcitonin and selective estrogen receptor modulators) and
bone anabolic agent (recombinant human Para-thyroid hormone). Maximum
patients in Pakistan were treated with bisphosphonate therapy due to
economic status however few patients were prescribed the recombinant
parathyroid hormone. There were no significant differences between
baseline characteristics of the two drug classes.
A total of 200 patients were examined out of which 120 patients met
inclusion criteria. These 120 patients involved 90 female and 30 male
patients. Patients were diagnosed with osteoporosis of knee, back and
lumber spine. Among 90 female patients11 of them withdrew therapy due to
personal reasons as well as due to occurrence of adverse effects and two
old ladies died not because of osteoporosis but because of other
complications. Among female patients 75% females were post-menopausal,
27% were osteopenic and 63% were osteoporotic. Out of 30 male patients
4 patients gave up due to the adverse effects they experienced. Hence
out of 26 male patients who continued therapy 33% male patients were
osteopenic and 77% were osteoporotic with age above 50 years. 69% of
the osteoporotic patients were treated with bisphosphonates and rest of
31% was recommended with rhPTH. The clinical design for current study
including parameters is given in Table 1.